[1] 孙可欣, 李荔, 王少明, 等. 2024年中国分地区恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2026, 48(3):400-412.
[2] WANG H, LI X, PENG R, et al.Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. Semin Cancer Biol, 2020, 71: 21-32.
[3] CERVANTES A, ADAM R, ROSELLÓ S, et al.Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 34(1): 10-32.
[4] ANGERILLI V, SABELLA G, CENTONZE G, et al.BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications[J]. Crit Rev Oncol Hematol, 2022, 172: 103647.
[5] CREMOLINI C, LOUPAKIS F, ANTONIOTTI C, et al.FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. Lancet Oncol, 2015, 16(13): 1306-1315.
[6] CREMOLINI C, ANTONIOTTI C, ROSSINI D, et al.Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2020, 21(4): 497-507.
[7] CREMOLINI C, ANTONIOTTI C, STEIN A, et al.Individual patient data Meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer[J]. J Clin Oncol, 2020: JCO2001225.
[8] KOPETZ S, GUTHRIE K A, MORRIS V K, et al.Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)[J]. J Clin Oncol, 2020, 39(4): 285-294.
[9] TABERNERO J, GROTHEY A, VAN CUTSEM E, et al.Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study[J]. J Clin Oncol, 2021, 39(4): 273-284.
[10] BENSON A B, VENOOK A P, ADAM M, et al.Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2024, 22(2 D).
[11] ELEZ E, YOSHINO T, SHEN L, et al.Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer[J]. N Engl J Med, 2025, 392(24): 2425-2437.
[12] PATNAIK A, KANG S P, RASCO D, et al.Phase Ⅰ study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J]. Clin Cancer Res, 2015, 21(19): 4286-4293.
[13] TOPALIAN S L, HODI F S, BRAHMER J R, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[14] TIAN J, CHEN J H, CHAO S X, et al.Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial[J]. Nat Med, 2023, 29(2): 458-466.
[15] MORRIS V K, PARSEGHIAN C M, BAHRAMBEIGI V, et al. Phase 1/2 trial of encorafenib, cetuximab,nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer[J]. Cancer Cell, 2025, 43(11): 2106-2118.e3.
[16] CHEN D, HUANG J-F, LIU K, et al.BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and Meta-analysis[J]. PLoS One, 2014, 9(3): e90607.
[17] XU Q, XU A T, ZHU M M, et al.Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a Meta-analysis[J]. J Dig Dis, 2013, 14(8): 409-416.
[18] KIKUCHI H, MATSUI A, MORITA S, et al.Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma[J]. J Natl Cancer Inst, 2022, 114(9): 1301-1305.
[19] LE D T, URAM J N, WANG H, et al.PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
[20] KUANG X, XU R, LI J.Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: systematic review and Meta-analysis of phaseⅢ randomized clinical trials[J]. Crit Rev Oncol Hematol, 2024, 198: 104357.
[21] MCGRANAHAN N, SWANTON C.Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
[22] WANG Q, JU X, WANG J, et al.Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies[J]. Cancer Lett, 2018, 438: 17-23.
[23] KIM R, TEHFE M, KAVAN P, et al.Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D[J]. Clin Colorectal Cancer, 2024, 23(2): 118-127.
[24] MELTZER S, NEGÅRD A, BAKKE K M, et al. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer[J]. Br J Cancer, 2022, 127(12): 2227-2233. |
